Cohen Capital Management’s Heron Therapeutics HRTX Stock Holding History

Cohen Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-142,330	Closed	-$3.35M	–	135
2019 Q4	$3.35M	Hold	142,330	–	–	0.72%	44
2019 Q3	$2.63M	Hold	142,330	–	–	0.61%	51
2019 Q2	$2.65M	Buy	142,330 +550	+0.4%	+$11K	0.62%	50
2019 Q1	$3.46M	Hold	141,780	–	–	0.84%	42
2018 Q4	$3.68M	Buy	141,780 +780	+0.6%	+$21.4K	1.02%	33
2018 Q3	$4.46M	Buy	141,000 +290	+0.2%	+$10.8K	1.01%	32
2018 Q2	$5.47M	Buy	140,710 +710	+0.5%	+$22.6K	1.27%	29
2018 Q1	$4.42M	Buy	+140,000	New	+$3.18M	1.04%	37

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cohen Capital Management's HRTX Position: Q1 2020 in Review

Cohen Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 142,330 shares — an estimated $3.35M sold.

Cohen Capital Management first reported a position in HRTX in Q1 2018 and held it in 8 quarters. The position peaked at $5.47M in Q2 2018. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

Cohen Capital Management reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
Cohen Capital Management sold 142,330 Heron Therapeutics shares in Q1 2020, an estimated $3.35M.
Cohen Capital Management first reported a position in Heron Therapeutics in Q1 2018 and held it in 8 quarters.
Cohen Capital Management's Heron Therapeutics position peaked at $5.47M in Q2 2018.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Cohen Capital Management's 13F filing for Q1 2020, filed 23 Apr 2020.